Adaptive Biotechnologies (NASDAQ: ADPT) net income
Adaptive Biotechnologies reported a net loss of $59.5m for fiscal 2025; in fiscal 2024 it reported a net loss of $159.5m. Earnings per share were −$0.39.
Adaptive Biotechnologies's best year of the last 8 was fiscal 2018. It reported a loss in 8 of those 8 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$59.5m | — | −21.5% | −$0.39 |
| 2024 | −$159.5m | — | −89.1% | −$1.08 |
| 2023 | −$225.3m | — | −132.3% | −$1.56 |
| 2022 | −$200.2m | — | −108.0% | −$1.40 |
| 2021 | −$207.3m | — | −134.3% | −$1.48 |
| 2020 | −$146.2m | — | −148.6% | −$1.11 |
| 2019 | −$68.6m | — | −80.6% | — |
| 2018 | −$46.4m | — | −83.4% | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Adaptive Biotechnologies net income compared with its sector
By net income for its latest fiscal year, Adaptive Biotechnologies ranks 273rd of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Adaptive Biotechnologies, −21.5%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 271st | Lucid Diagnostics | −$58.0m | −1,232.7% |
| 272nd | Nautilus Biotechnology | −$59.0m | — |
| 273rd | Adaptive Biotechnologies | −$59.5m | −21.5% |
| 274th | Onkure Therapeutics | −$59.5m | −1,729.6% |
| 275th | Climb Bio | −$59.9m | — |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Adaptive Biotechnologies
- How much did Adaptive Biotechnologies earn in fiscal 2025?
- Adaptive Biotechnologies reported a net loss of $59.5m for fiscal 2025. In fiscal 2024 it reported a net loss of $159.5m.
- What are the earnings per share of Adaptive Biotechnologies?
- They were −$0.39 in fiscal 2025, compared with −$1.08 in fiscal 2024.
- Where does Adaptive Biotechnologies rank in its sector by net income?
- It ranks 273rd of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Adaptive Biotechnologies come from?
- From the annual report (Form 10-K) that Adaptive Biotechnologies files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Adaptive Biotechnologies files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018. More on Adaptive Biotechnologies: the Adaptive Biotechnologies page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.